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ABSTRACT
Roseofilum reptotaenium is a marine cyanobacteria responsible for the loss of 50% of
corals worldwide due to Black Band Disease (BBD). Investigating the basis for secondary
metabolite production by R. reptotaenium cultures revealed a suite of potent anti-malarial and
anticancer compounds that likely include dolastatin 10 and monomethyl auristatin D (MMAD).
These R. reptotaenium cultures are non-axenic (not pure monocultures) and R. reptotaenium
appears to require the presence of several heterotrophic bacteria to survive. Scanning Election
Microscope (SEM) images show closely associated bacteria. Preliminary metagenomic analysis
indicates three dominant non-cyanobacterial phyla: Bacteroidetes, Planctomycetes, and
Proteobacteri (α-proteobacteria accounted for >50% of the entire community). We are explored
the role of these bacteria with R. reptotaenium in producing the complex of dolastatin/MMAD
compounds, seeking to understand the chemical ecology and genetic basis by which these
compounds are produced. The potential involvement of the dolastatin-like suite of compounds in
Black Band Disease in corals merits further study given the destructiveness of this disease on
corals worldwide.
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INTRODUCTION
Coral reefs cover about 600,000 square kilometers of the Earth’s surface (Crossland et al.
1991), and are among the most diverse biological ecosystems in the world (Lesser et al. 2007).
Coral reefs provide several important physical, biological, and cultural services (Cesar 2002).
They serve as a habitat for many different marine organisms, thereby maintaining biodiversity
(Cesar 2002). They are also a tremendous source of marine products (e.g., seafood, raw
materials, jewelry, and medicinal compounds), which are valued at approximately $375 billion
per year (Richardson 1998).
Coral reef ecosystems have been degraded at an alarming rate because of the impact of
several threats derived from human activity (e.g., over-exploitation in fishing, non-sustainable
tourism practices, and pollution) and natural factors (e.g., tropical storms, climatic changes, and
coral diseases) (Lesser et al. 2007). Coral diseases are considered a major cause of coral reef
loss. A survey of coral reef diseases in Florida Keys reef in 2001 showed that the number of
locations exhibiting coral disease increased by 80%, and the the rate of coral mortality increased
by 60% compared to data from 1996 (Santavy et al. 2001). Black band disease (BBD) is one of
six dominant coral diseases infecting reefs globally and contributes to 50% of the loss of corals
by the disease (Harborne et al. 2006; Harvell et al. 2001; Peters 1984).
Black Band Disease (BBD) is marked by dense black bands or rings that circumscribe
regions of damaged coral tissue (Garzón et al. 2001), and has been show to be caused by the
marine cyanobacterium Roseofilum reptotaeneum (Fig.1). BBD was first observed on stony
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corals in the Caribbean in the 1970s (Antonius 1977), but is now found on tropical and
subtropical coral reefs worldwide (Sutherland et al 2004). BBD is a seasonal disease, with high
prevalence when the temperature is above 29-30°C (Richardson et al. 2014). BBD can
progress at a rate of 0.3 - 1 cm per day, and can kill a coral colony over several months.

+

Roseofilum
reptotaenium

Coral reefs

Black Band
Disease

Figure 1. R. reptotaenium (left) causes Black Band Disease (see red arrow) in corals (Scale bar
of R. reptotaenium filaments is 10 µm)
According to Richardson’s hypothesis (2014), BBD is caused by the synergistic action of
microcystin toxin produced by R. reptotaenium and hydrogen sulfide produced by sulfate
reducing bacteria (Richardson et al. 2014). These conditions are believed to kill the symbionts
(Symbiodinium sp.) living in corals, leading to bleaching and coral degradation. Coral bleaching
is the phenomenon that happens when the symbiotic interaction between coral hosts and
symbionts is disrupted; corals will lose their algae symbionts and algal photosynthetic pigments,
then turn to white color (Correa et al. 2009). Symbiodinium is the dinoflagellate living in
symbiosis with corals and their relatives (Pochon et al. 2006). Corals provide a safe environment
and the necessary compounds for Symbiodinium’s photosynthetic process while Symbiodinium
supplies photosynthetically fixed carbon (sugars, and lipids) back to corals (Correa et al. 2009;
Kirk et al. 2005). The sea anemone Aiptasia (Fig. 2) is a genus of symbiotic cnidarian in the
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Anthozoa class, and also lives in symbiosis with Symbiodinium sp. The symbiosis relationship
between Aiptasia and Symbiodinium sp. is similar to the relationship between corals and
Symbiodinium sp., and Aiptasia is often used as a laboratory model to for corals, given the
endangered nature of many corals.

Figure 2. The sea anemone Aiptasia sp. isolated from Florida Keys and cultivated in the
laboratory.
Richardson demonstrated that R. reptotaenium cultures can cause BBD-like symptoms on
Diploria strigosa stony coral fragments after 7 days of cultivation in the laboratory; after 28
days, the coral skeleton completely disintegrated (Richardson et al. 2014). However, exposure of
healthy coral fragments to microcystin at concentrations of 50-100 µM did not appear to injure
the coral and only resulted in a decreased number of heterotrophic bacteria on the coral surface
(Richardson et al. 2009). R. reptotaenium is a phycoerythrin (brownish-red), motile, unbranched
filamentous cyanobacterium first classified as Oscillatoria submembranaceae (1981) and then as
Phormidium corallyticum (1983) based on morphology. In 2009, these were re-classified as
Pseudoscillatoria coralii based on 97% sequence similarity (Rasoulouniriana et al. 2009).
However, Pseudoscillatoria coralii is a dark blue-green algae with phycocyanin, not
phycoerythrin, the pigment dominant in the brownish-red algae. Taxonomic revisions in 2012 by
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Casamatta re-classified these as Roseofilum reptotaenium and further demonstrated in the
laboratory that R. reptotaenium was the causative agent of BBD (Casamatta et al. 2012). A R.
reptotaenium type strain has been deposited at the National Center for Marine Algae and
Microbiota (NCMA) (at the Bigelow Laboratory for Ocean Sciences) and maintained as
CCMP3313, which is the culture source for the work described in this thesis.
R. reptotaenium grows filamentously, with filaments about 3.0-3.9 µm wide and an
average cell length of 2.5-4.0 µm. R. reptotaenium can grow photoautotrophically or
mixotrophically, but not heterotrophically (Richardson 2003). The R. reptotaenium cultures are
non-axenic (i.e., not pure monocultures) and R. reptotaenium appears to require the presence of
several heterotrophic bacteria to survive. R. reptotaenium experiences the highest growth rate on
L1 salt water medium in comparison to ASNIII, F2, and IMK culture media (Buerger et al.
2016). R. reptotaenium exhibits clumping behavior and grows faster in non-disturbed conditions
than in stirred or agitated culture conditions (Richardson et al. 2014). Clumping behavior is
believed to lead to self-shading and reduced exposure to high intensity light (Castenholz 1988).
In 2011, it was determined through enzyme-linked immunosorbent assay (ELISA) tests
that R. reptotaenium cultures produce the cytotoxin microcystin-LR at a concentration of 20-40
µg g-1 biomass (Stanić et al. 2011). Microcystins (MC) are a group of cyclic heptapeptide toxins
produced by the cyanobacterial genera Microcystis, Oscillatoria, Planktothrix, Anabaena, and
Nostoc (Niedermeyer et al. 2012). MCs contain 80 structural variants with the general structure
cyclo-(D-alanine1- X2-D-MeAsp3-Z4-Adda5-D-glutamate6-Mdha7), where X and Z represent two
variable L-amino acids (Fig. 3-left) (Sheng et al. 2007). Microcystin-LR (MC-LR) is the most
toxic variant in which the two variable L-amino acids are leucine and arginine (Fig. 3-right)
(MacKintosh et al. 1990). Microcystin-contaminated drinking water represents a serious human
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health risk due to the damaging liver effects of microcystins once consumed (Hooser 2000;
MacKintosh et al. 1990; Falconer et al. 1981). Microcystins can also act as tumor promoters,
causing liver cancer (Hooser 2000). Experimentally, it has been shown to directly damage the
livers of rat and mice after a few minutes of exposure (Falconer et al. 1981).
7
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1
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2
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Microcystins LR
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Figure 3. Molecular structure of Microcystins and Microcystin LR
In 2007, studies were initiated with MC-LR to determine its potential as an anticancer
compound on the basis of two characteristics (Monks et al. 2007). Firstly, MC-LR is only toxic
after being absorbed into liver cells due to its poor membrane permeability (Monks et al. 2015).
Secondly, MC-LR kills cancer cells through phosphatase inhibition, but not by inducing
apoptosis (Monk et al. 2015). Therefore, MC-LR can work effectively against apoptosis-resistant
cancer cell lines. The action of microcystins against cancer cells is based on the activity of
organic anion transporting polypeptides (OATP) (Daily et al. 2010; König et al. 2006). OATP1B1 and OATP-1B3 are two human proteins that can mediate the transport of microcystins from
blood to liver cells. OATP-1B1 is fairly abundant in liver tissues while OATP-1B3 is more
widely distributed in liver cancer cells than in healthy cells (Monk et al. 2015). The selectivity
that favors OATP-1B3 over OATP-1B1 can offer a therapeutic window for the respective
compound (Monk et al. 2015; Monks et al. 2007; Sainis et al. 2010).
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In 2012, two hundred and seven algal cultures were sent from the Bigelow
laboratory/NCMA to the National Center of Natural Products Research (NCNPR) for bioactivity
screenings. The preliminary data suggested that R. reptotaenium cultures might possess potent
antimalarial activity. While promising, the materials sent (15 mL of liquid culture per algal
strain) were not sufficient for initiating follow-up experiments. R. reptotaenium also proved very
difficult to culture under laboratory conditions by former research groups (Bigelow and
Richardson labs). Owing to scientists at the NCNPR not having algal culturing expertise,
research capacity, or sufficient interest to follow-up, this collaborative effort stalled for several
years. From the start, the Hom lab was interested in collaborating with Dr. Michael Lomas at the
Bigelow Laboratory to better understand the chemical and microbial ecology of algae within the
NCMA culture collection. In 2015, I started working on studying several marine algal cultures
before focusing on R. reptotaenium, given its relatively faster cell culturing times.
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METHODS
R. reptotaenium culturing and extractions
Erlenmeyer flasks containing 1.5 L of L1 seawater medium (Guillard et al. 1993) (see
recipe in Appendix A) were inoculated with 0.5-gram of wet R. reptotaenium biomass. Flasks
were covered twice by multipurpose white paper (Georgia-Pacific Consumer Products, Atlanta,
GA) and maintained at 30°C and 27 µEm-2s-1 under a 12:12 light/dark cycle of cool-white light.
R. reptotaenium cultures were centrifuged at 2000 g for 3 minutes to separate biomass from
supernatant for downstream secondary metabolite extraction (Fig. 4). As described in greater
detail below, secondary metabolites present in the supernatant and the biomass were extracted by
ethyl acetate and methanol, respectively, and solvent-evaporated to generate “crude” extracts.
These crude extracts were further fractionated, dried down, resuspended in dimethylsulfoxide
(DMSO), and submitted for antimalarial and anticancer assays, and chemical characterization
(LC-MS/MS). DNA from fragments of biomass was also isolated for metagenomic 16S rDNA
amplicon sequencing (Fig. 4).
Biomass extractions.
To extract secondary metabolites from R. reptotaenium cells, 300 mg of biomass was
transferred to a 50 mL falcon containing 30 mL of methanol, and sonicated for 5 minutes at
400Hz using a Branson M1800 ultrasonic bath (Branson Ultrasonics, Dansbury, CT). The
resulting methanol slurry was centrifuged at 22,000g for 3 minutes. The biomass pellet was then
subjected to two more extractions with methanol. Methanol supernatants were pooled and
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evaporated at 30°C for 20 minutes to generate what we refer to as “crude biomass
extracts.” Genomic DNA was isolated from two hundred mg of fresh R. reptotaenium biomass
from 2 week-old and 8 week-old cultures. Genomic DNA was extracted using 500 µl of phenol:
chloroform: isoamyl alcohol (25:24:1), cleaning up by 500 µl of isopropanol, precipitated
overnight in 200 µl of ethanol, and re-dissolved in 20 µl TE buffer. The prokaryotic composition
of R. reptotaenium cultures was characterized using a 250-bp portion of the bacterial 16S rRNA
gene and Illumina MiSeq sequencing as previously described (Kozich et al. 2013; Jackson et al.
2015). Samples were pooled, spiked with 5 % PhiX (Jackson et al. 2015), and sequenced at the
University of Mississippi Medical Center Molecular and Genomics Core Facility (courtesy of
Dr. Colin Jackson). Raw sequences were analyzed by mothur 1.40.0 (Schloss et al. 2009, 2011).
Sequences were aligned against the SILVA V4 16S rRNA database (Quast et al. 2013), and
chimeras were detected using UCHIME (Edgar et al. 2011). Valid sequences were classified
using the Greengenes 16S rRNA classification scheme (DeSantis et al. 2006), with chloroplast
(and mitochondrial) sequence contaminants removed. Bacterial sequences were grouped into
operational taxonomic units (OTUs) based on 97 % sequence similarity.
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Figure 4. Protocol schematic for metabolite extraction from R. reptotaenium culture (The
information in the red box is represented in Fig.5).
Supernatant extractions
The cell-clarified supernatant of R. reptotaenium cultures was transferred to a 1.5 L
separatory funnel and combined with an equal volume of ethyl acetate (EtOAc) organic solvent.
The funnel was inverted gently ten times in order to allow the partitioning of the active
compounds into the EtOAc organic phase. After several minutes of allowing aqueous and
organic phases to separate, the lighter EtOAc phase (density ~ 0.902 g/cm3) was isolated to
ensure that any trace amounts of water were removed, while the supernatant were subjected to
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two more rounds of EtOAc extraction. EtOAc phases were combined and evaporated using a
BUCHI rotovapor R100 rotary evaporator (BUCHI Corp., New Castle, DE) for 45 minutes at
30°C to generate what we refer to as “crude supernatant extracts” (Fig.5).
Load
supernatant +EtOAc

Agitate

Separate

Drain

Evaporate

EtOAc
Supernatant
Rotovap machine

Figure 5. Protocol schematic for the generation of the crude extracts from the supernatant of the
R. reptotaenium culture.
Purification of crude extracts by reverse phase chromatography.
Reverse-phase chromatography (RPC) is widely used in drug-discovery to purify potent
compounds from crude extracts. RPC involves two parts, a non-polar hydrophobic stationary
phase and a polar hydrophilic mobile phase. Due to the polar/non-polar chemistry of the
mobile/stationary phases, polar compounds that do not interact with the surface of stationary
phase are eluted first while the non-polar compounds are eluted last. The stationary phase usually
contains a long alkyl chain, and we used a column with 18 carbons (C18); for the mobile phase,
we used methanol (MeOH) or acetonitrile (CH3CN), with CH3CN being a slightly more polar
solvent (Mantoura et al. 1983).
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Crude extracts were dissolved in 1mL of 1:1 methanol: water and loaded onto a C18
column in 100 mg portions, and eluted by a series of six MeOH concentrations (0%, 20%, 40%,
60%, 80%, 100%), with a final elution using 100% acetone. These seven solvent fractions were
individually dried by rotavap evaporation at 30°C for 5 min, dissolved in DMSO, and submitted
for antimalarial and anticancer assays, and chemical characterization (LC-MS/MS) (Fig. 6)

Figure 6. R. reptotaenium crude extracts (biomass and supernatant) were eluted by methanol
(MeOH) at different concentration through the C18 column.
Similarly, 100 mg crude extracts dissolved in 1mL of 1: 1 methanol: water were loaded
onto a C18 column and eluted by a series of six CH3CN concentrations (0%, 20%, 40%, 60%,
80%, 100%), followed by 100% Acetone. These seven purified fractions were also submitted for
antimalarial and anticancer assays, and chemical characterization (LC-MS).
Characterizing potent compounds in the crude extracts by LC-MS.
Liquid chromatography-mass spectrometry (LC-MS) is an analytical chemistry technique
that combines the physical separation capabilities of high performance liquid chromatography
(HPLC) and the mass analysis capabilities of mass spectrometry (MS) (Pitt 2009). HPLC is a
11

technique which forces a liquid solution (mobile phase) containing potential drug compounds
into a C18 silica column (stationary phase) by high pressure. Due to varying polarities of the
compounds present in the solution, there are time differences in elution of the compounds. MS is
an analytical technique which is used to elucidate the chemical structures of molecules by
determining the mass and elemental compositions of a given sample (Dass 2007). MS ionizes the
molecules by an electron beam or UV light to produce charged molecules (ions). These ions are
then separated by electromagnetic fields based on their mass-to-charge ratio (Dass 2007).
LC-MS/MS is similar to LC-MS except LC-MS/MS generates secondary MS
fragmentations of the primary precursor ion. The advantages of MS/MS are increased sensitivity
and the ability to provide more detailed structural information based on the sub-fragmentation
patterns. In collaboration with Dr. Yan-Hong Wang (NCNPR), the active fractions identified in
the antimalarial and anticancer assays were submitted for chemical characterization by LCMS/MS (Waters ACQUITY UPLC system coupled with Xevo G2-S ToF mass spectrometer)
using the gradient conditions shown below (Table 1).
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Table 1. Gradient conditions used for LC-MS/MS analysis of R. reptotaenium extracts
Flow

% Acetonitrile with

% Water with

(mL/min)

0.05% formic acid (v/v)

0.05% formic acid (v/v)

0.00

0.30

30.0

70.0

7.00

0.30

70.0

30.0

10.00

0.30

100.0

0.0

15.00

0.30

100.0

0.0

Time

Bacterial Community Composition of R. reptotaenium Cultures.
Individual bacterial strains were isolated from R. reptotaenium cultures by classic
cultivation methods. 10 mg of R. reptotaenium biomass was streaked on 1.5% agar plates made
with L1 medium. Plates were stored at 30°C for 4 days for bacterial colonies to develop.
Bacterial colonies were selected based on the differences of color and morphology, and then
made clonal by continuously streaking into new agar plates for four more times (Fig. 7). Single
clonal bacterial colonies were selected and resuspended in 15 µl of nuclease free water in 0.2 mL
PCR tubes, heated at 98oC for 15 minutes, then centrifuged at 22,000 g for 3 minutes to pellet all
of the cellular debris. The supernatants (13 µl) containing bacterial DNA were then transferred to
new 0.2 mL tubes for PCR amplification.
Bacterial 16S rRNA genes were amplified using primers 16S rRNA forward (5’ - AGA
GTT TGA TCC TGG CTC AG - 3’) and 16S rRNA reverse (5’ - ACG GCT ACC TTG TTA
CGA CTT - 3'). Final PCR reaction concentrations were as follows: 5 µl of 5X PCR buffer, 1 µl
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of 10 µM forward primer, 1 µl of 10 µM reverse primer, 0.25 µl polymerase, 3 µl DNA, and
14.75 µl nuclease-free water added to a final volume of 25 µl. PCR reactions were carried out
with an initial denaturing step at 95oC for 2 minutes, then followed by 30 cycles of 95oC for 15
seconds, 68oC for 15 seconds, and 72oC for 45 seconds, with a final extension step at 72oC for 5
minutes. The PCR products were run on an agarose gel (1% agarose, 1X Lithium Acetate Borate
Buffer, 200V, 0.2 A) for 15 minutes, along with the negative control (nuclease-free water) to
prior verify the qualification of PCR products. PCR products were purified using a QIAquick
PCR Purification Kit (QIAGEN Inc., Valencia, CA). The 4Peaks software was used to clean up
the bad signal peaks, then BLAST was used to analyze sequences in order to identify the closest
relative in GenBank based on the percentage of identity and query cover
(https://www.ncbi.nlm.nih.gov/blast/).
To determine the minimum medium requirements that would enable these isolated
bacteria to grow, they were grown in three different types of media with six replicates per each
treatment for 9 days: (1) L1, (2) L1 with 0.25% bactopeptone (HiMedia Laboratory Pvt. Ltd.,
Maharashtra-India), (3) L1 with 25 µM sucrose. Potential secondary metabolites of these
bacteria cultures (grown in L1 with 25 µM sucrose medium) in supernatant and biomass were
extracted by EtOAc and MeOH, respectively, as described above and submitted to antimalarial
assays.
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Figure 7. Protocol schematic for the identification of the roles of the bacteria community in R.
reptotaenium culture.
Scanning electron microscopy (SEM) of R. reptotaenium Culture Biomass.
In scanning electron microscopy, a beam of electrons is used to image surface properties
of a specimen at high resolutions unattainable by conventional light microscopy (~1 nm) (Wells
1974). Biological samples must be fixed to enable high contrast imaging.
Fixation of the samples for SEM imaging
Two and 8 weeks old suspensions of R. reptotaenium were fixed in 4% glutaraldehyde
buffered with 0.1M sodium phosphate (pH 7.4) for 2 hours, then rinsed in the 0.1M sodium
phosphate buffer for 30 min. Samples were gradually dehydrated in an ethanol series (25%, 50%,
75%, 95%) for 40 min at each gradation, followed by three 20 min washes in 100% ethanol. The
cells were then processed in an automatic critical point dryer Leica Microsystems model EM
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CPD300, mounted on aluminum SEM stubs, and sputter-coated with osmium. Samples were
imaged using a JSM-7500F 5.0 kV SEM (JEOL USA, Inc., Peabody MA) at the Center for
Advanced Microscopy in Michigan State University.
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RESULTS
R. reptotaenium culturing
The original 15 mL R. reptotaenium culture we obtained from Bigelow laboratory
contained only a small white clump of R. reptotaenium biomass. At the beginning, we inoculated
the culture into 500 mL of L1 media and maintained it at 30°C and 27 µEm-2s-1 under a 12:12
light/dark cycle of cool-white light but without covering. Under these conditions, R.
reptotaenium biomass did not increase nor was there any color change from white to red even
after two months. The culture were also maintained under the light intensity equal to the intensity
inside 2 layers of paper, 5 µEm-2s-1, which were cut off by transparency films 75% nano ceramic
solar (Tint Depot, Houston, TX). However, the R. reptotaenium still did not increase its biomass
or change its color. It was believed that the white paper may decrease the light intensity and
change the light spectrum.
When we covered the flask twice by multipurpose white paper (Georgia-Pacific
Consumer Products, Atlanta, GA) and maintained under the same conditions as described above,
the culture increased its biomass and started to change the color from white to red after 4 weeks.
We also saw that some R. reptotaenium filaments start to adhere onto the walls of the culture
flasks, forming ring patterns approximately 3 mm in diameter. (Fig. 8).
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R. reptotaenium
ring patterns

Figure 8. Ring patterns of an undisturbed 4 week-old R. reptotaenium culture.
Characterizing potent antimalarial/anticancer compounds in R. reptotaenium
extracts
Antimalarial activity of R. reptotaenium crude extracts as a function of the duration of
culturing.
In collaboration with Dr. Melissa Jacob’s group at the National Center for Natural
Products Research (NCNPR), the anti-malarial potential of bioactive metabolites derived from
the R. reptotaenium culture was evaluated in vitro on a chloroquine (CQ) -sensitive strain (P.
falciparum D6) and a CQ-resistant strain (P. falciparum W2). P.falciparum W2 (D6) IC50 is the
dose that inhibits 50% growth of P.falciparum W2 (D6) relative to the control. Vero cells
(monkey kidney cells) were used as a control to estimate general toxicity of the extracted
compounds. The selective index (SI) is the ratio between the IC50 of the control (Vero) cells
over the IC50 of P. falciparum and for promising drug lead compounds, usually falls within the
range of 9-11 (M. Jacob, personal communication). The R. reptotaenium extracts generally
showed a similar inhibition response on the P. falciparum D6 and W2 strains; we will show
representative results using the W2 strain (Figs. 9-11) (data for the D6 strain can be found in the
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appendix (Tables 7-9). Antimalarial assays were repeated twice; as the average data were very
similar to the values of replicates and given only two replicates, error bars are not shown.
R. reptotaenium crude extracts were found to produce secondary metabolites with potent
antimalarial activity. The antimalarial activity of R. reptotaenium crude extracts increased as the
duration of culturing increased. For example, 8 week-old R. reptotaenium supernatant crude
extracts inhibited 50% growth of P.falciparum W2 parasite with a dose of 196 ng/mL while
~15,000 ng/mL of 2 week-old R. reptotaenium supernatant crude extract was needed for a
similar effect (Fig. 9-left). The biomass crude extracts at 8 weeks showed more potent
antimalarial activity than at 2 weeks, IC50=5,500 ng/mL vs to ~17,000 ng/mL. The supernatant
crude extracts were generally more potent than the biomass crude extracts at the same age. For
example, the supernatant extracts at 8 weeks was 28 times more active than the biomass extracts
at the same age (IC50 of 196 ng/mL compared to 5,500 ng/mL) (Fig. 9-left).
The SI value increased over time, meaning that the crude extracts of older cultures were
more active than those of the younger cultures. The SI value of supernatant crude extracts
increased dramatically from 3 in 2 weeks to 243 in 8 weeks (Fig.9-right). The R. reptotaenium
culture showed the best antimalarial activity in the supernatant extracts at 8 weeks (the longest
culturing time examined), with an IC50 <196 ng/mL, and an SI value of 243 (Fig.9). We
speculate that if we continue maintaining the culture more than 8 weeks, the antimalarial activity
will keep increasing, although we have not tried to do it yet due to the lack of culturing capacity.
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Figure 9. Growth inhibition (IC50) P.faciparum W2 (left) and selectivity index (SI) of inhibition
vs. control (right) of R. reptotaenium crude extracts according to the culturing duration.
Eight week-old R. reptotaenium crude supernatant and biomass extracts (100 mg each)
were purified through a C18 column and eluted using different concentrations of methanol
(MeOH) followed by acetone. The yields for each fraction (after drying) are shown in Table 2.
These eluted fractions were then submitted for antimalarial assays.

20

Table 2. The dry-weight yield of fractions from supernatant and biomass extracts eluted using
different concentrations of methanol.
Fractions

Supernatant extracts (mg)

Biomass extracts (mg)

Water

82.54

71.88

20% MeOH

1.11

2.74

40% MeOH

0.79

1.96

60% MeOH

0.79

2.34

80% MeOH

1.27

1.18

100% MeOH

0.79

0.78

100% Acetone

0.95

1.18

Total

88.25

82.04

The water, 20% MeOH, and 40% MeOH eluted fractions from the crude supernatant
crude extracts did not show any antimalarial activity. The five active fractions were 100%
MeOH and 100% acetone from supernatant extracts, and the 80% MeOH, 100% MeOH, 100%
acetone fractions from the crude biomass extracts. In the supernatant extracts, the 100% acetone
fraction was most active, with an IC50 of 0.22 ng/mL and an SI of 216 (Fig. 10); the 100%
MeOH fraction was slightly less active, with an IC50 of 1 ng/mL and an SI of 48. However, the
yield of these fractions were extremely small, with only 0.95 mg of the 100% acetone fraction
and 0.79mg of the 100% MeOH fraction from 100 mg of crude extracts (Table 2). The 100%
acetone fraction derived from the crude supernatant extract was 27 times more potent than from
the 100% acetone fraction biomass (0.22 ng/mL compared to 6 ng/mL).
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Figure 10. Growth inhibition (IC50) P. faciparum W2 (left) and the selectivity index (SI) of
inhibition vs. control (right) of R. reptotaenium fractions eluted by methanol (MeOH).
Another set of 8 week-old crude supernatant and biomass extracts (100 mg per each)
were loaded through a C18 column and eluted using different concentrations of acetontitrile
(CH3CN) followed by acetone. The yields of these fractions are shown in table 3. These fractions
were then submitted for antimalarial assays.
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Table 3. The dry-weight yield of fractions from supernatant and biomass extracts eluted using
different concentrations of acetonitrile.
Fractions

Supernatant extracts (mg)

Biomass extracts (mg)

Water

91.3

91.3

20% Acetonitrile

3.1

2.5

40% Acetonitrile

0.3

0.2

60% Acetonitrile

0.3

0.3

80% Acetonitrile

0.1

0.1

100% Acetonitrile

0.3

0.1

100% Acetone

0.2

0.3

Total

95.6

94.8

The 100% acetone fractions eluted from the crude supernatant extracts were most potent,
with an IC50 of 0.5 ng/mL and an SI of 1134 (Fig. 11), although the yield of this fraction (dryweight) was low at 0.2 mg over 100 mg of input extract (Table 3). The antimalarial activity was
spread out in the three last fractions (80% methanol, 100% methanol, and 100% acetone) when
the crude extracts were purified by MeOH. In contrast, the antimalarial activity was focused on
the last fraction (100% acetone) when the crude extracts were purified by acetonitrile.
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Figure 11. Growth inhibition (IC50) P. faciparum W2 (left) and the selectivity index (SI) of
inhibition vs. control (right) of R. reptotaenium purified fractions by different concentrations of
acetonitrile (CH3CN).
Anticancer activity of R. reptotaenium crude extracts
In collaboration with Dr. David Pasco of the NCNPR, we determined that 8 week old R.
reptotaenium crude extract inhibited more than 80% of Temodar drug-resistant glioblastoma
brain cancer cells with an IC50 of ca. 0.1 µg/mL. However, at the same concentration, this
extract only inhibited <40% of the triple-negative breast cancer cell growth. Generally, at
moderate to high concentrations, the R. reptotaenium crude extracts were particularly effective
against the Temodar drug-resistant glioblastoma cell line (Fig.12)
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glioblastoma (T98G; brain cancer) and triple-negative breast cancer (MDA-MB-231) cell lines.
LC-MS of the active fractions
One gram of the 8 week-old R. reptotaenium crude supernatant extracts (from 40 L of
culture) were fractionated using a C18 column and eluted by different concentrations of
methanol and acetone as described above. The two most biologically active fractions (100%
methanol and 100% acetone) were combined for a total of 13 mg (dry weight) of what we refer
to as “highly active extract.”
The five active fractions eluted by methanol (supernatant-100% methanol, supernatant100% acetone, biomass-80% methanol, biomass-100% methanol, and biomass-100% acetone),
two active fractions eluted by acetonitrile (supernatant-100% acetone and biomass-100%
acetone), and the 13 mg of highly active extract were submitted for LC-MS analysis. All active
fractions showed a similar LC elution profile within the 2-4.5 min range (Fig. 13). The 13 mg of
the highly active extract was divided into 4 regional parts, and submitted for antimalarial assays.
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Part 2, which contained the peaks in the 2-4.5 min region in Fig.14, was the most active part with
an IC50 <4.9 ng/mL and SI of 120 (Table 4).
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Figure 13. Liquid chromatography of the active fractions. From top to bottom: five active
fractions eluted by methanol: supernatant-100% methanol, supernatant-100% acetone, biomass80% methanol, biomass-100% methanol, and biomass-100% acetone; two active fractions eluted
by acetonitrile: supernatant-100% acetone and biomass-100% acetone; 13 mg of the highly
active extract (100% methanol and 100% acetone elution from the supernatant crude extract).
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0-2min

2-4.5min

4.5-9.0min

9.0-12.0min

Figure 14. Liquid-chromatography of the supernatant-acetone 100% fraction.
Table 4. Antimalarial activities of different parts of an LC elution of 13 mg of the highly active
extract (from 100% methanol and 100% acetone fractions of 8-week old supernatant crude
extract). Part 2 contains the same peaks as those seen in Fig. 13 in the 2-4 min region.
P. falciparum W2 IC50
Parts

P. falciparum W2 SI
(ng/mL)

Part 1: 0-2.0 min

>1190

1

Part 2: 2.0-4.5 min

<4.9

120

Part 3: 4.5-9.0 min

109

>11

Part 4: 9.0-12.0 min

>1190

1

Combination

14

>86.5

Using the Table 1 LC gradient elution conditions, five compounds were repeatedly found
in the active 2-4 min region (Table 5). The molecular weights of these compounds often differed
by a mass of 14, which is equivalent to a methylene (CH2) group of methylene. The MS output
of two representative compounds consistently found are shown in Fig.15.
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Figure 15. MS and MS/MS spectra of two representative compounds repeatedly found in the
active fractions.
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SciFinder (Wagner 2006) was used to search known compound databases for molecules
having the same molecular weight, molecular formula, and retention times. The compound with
a molecular weight of 785 was identified as likely to be dolastatin 10, a known potent anticancer
and antimalarial compound (Pettit et al. 1989). The compound with a molecular weight of 770
was identified as likely to be monomethyl auristatin D (MMAD), a derivative of dolastatin 10
generated by purely synthetic means today (Miyazaki et al. 1995) (Table 6). In order to verify
our assumption, pure dolastatin 10 and MMAD were obtained as the standards, and LC-MS/MS
co-injection experiments with these standards and the highly active extract confirmed the identity
of dolastatin 10 (Fig. 16) and MMAD in the active fractions (Fig. 17)
Table 5. The probable formula and putative compound name based on molecular weight and
retention time
Retention time

Molecular

Most probable
Putative compound

(min)

weight

formula

2.75

757

C40H65N6O6S

Other compound

3.05

771

C41H67N6O6S

Monomethyl auristatin
(MMAD)

3.33

785

C42H69N6O6S

Dolastatin 10

3.59

801

C42H69N6O7S

Other compound

3.91

815

C43H71N6O7S

Other compound
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EIC (785 Da) chromatograms of the active fraction,
dolastatin 10, and mixture of dolastatin 10 plus the
active fraction

MS spectra of the active fraction, dolastatin 10, and
mixture of dolastatin 10 plus the active fraction

Figure 16. The chromatogram (above) and mass-spectrometry (below) of dolastatin 10 alone,
dolastatin 10 co-injected with the 13 mg highly active fraction, and the 13 mg highly active
fraction alone (100% methanol and 100% acetone fractions of the supernatant crude extract)

31

EIC (771 Da) chromatograms of the active fraction,
MMAD, and mixture of MMAD plus the active fraction

MS spectra of the active fraction, MMAD, and mixture of
MMAD plus the active fraction

Figure 17. The chromatogram (above) and mass-spectrometry (below) of MMAD alone,
MMAD co-injected with the 13 mg highly active fraction, and the 13 mg highly active fraction
alone (100% methanol and 100% acetone fractions of the supernatant crude extract).
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With Drs. Amar Chittiboyina and Yan-Hong Wang of the NCNPR, a possible biogenesis
diagram of dominant metabolites in the active fractions was proposed (Fig. 18). The compound
with molecular weight of 785 was likely dolastatin 10. The compound with molecular weight of
771 was likely MMAD. The compounds with molecular weights of 757, 801, and 815 were the
other compounds (Table 5).

Figure 18. Proposed biogenesis of dominant metabolites in active fractions
Understanding the role of the bacteria community in R. reptotaenium culture.
Bacterial strains isolated from an 8 week-old R. reptotaenium culture by 16S rRNA gene
amplification.
Thirty-four isolated bacterial colonies (obtained after repeated passage) were randomly
selected and submitted for 16S rRNA gene amplification. The following six bacterial strains
were identified: Labrenzia (alexandrii), Labrenzia (aggregate), Kordiimonas sp., Muricauda sp.,
Stappia sp., and Phyllobacterium sp. (Table 5). Labrenzia (alexandrii) and Muricauda sp. were
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the two most abundant species, accounting for 29/34 colonies, while Labrenzia alexandrii was
the least dominant species with only 6/34 colonies.
Table 6. The bacterial identity and frequency of colonies isolated from an 8 week-old R.
reptotaenium culture (out of 34 randomly sampled colonies).
Bacterial strains

The number of colonies (out of 34 total)

Labrenzia alexandrii

2

Labrenzia aggregata

10

Kordiimonas sp.

4

Muricauda sp.

10

Stappia sp.

4

Phyllobacterium sp.

4

Total

34

Labrenzia sp., Stappia sp., Koidiimonas sp, Phyllobacterium sp. belong to αProteobacteria while Muricauda sp. are in the Flavobacteria phylum. All of these bacterial
strains are marine heterotrophic, gram-negative bacteria. Their sizes range from 0.1 to 3.0 µm,
and are generally rod-shaped. More detailed information of the six bacterial strains can be found
in the Appendix (Table 10).
Growing bacterial strains in different types of media and biological activity of extracts
The six different culturable bacteria isolated from the R. reptaenium polyculture were
grown in three different types of media over a 9 day-period to determine the minimum medium
in which these species could grow. The L1 media was the negative control while the L1 with
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peptone media was the positive control. The heterotrophic bacteria did not grow in L1 media due
to a lack of a carbon source. Fig. 19 showed that L1 containing sucrose [0.25 µM] was the
minimum medium in which the six bacterial strains could grow after 9 days.

9 days

Figure 19. Species isolated and identified by 16S gene sequencing from the R. reptotaenium
polyculture (A. Labrenzia alexandrii, B. Labrenzia aggregata, C. Kordiimonas sp., D.
Muricauda sp., E. Stappia sp. F. Phyllobacterium sp. G. 6 of the bacteria (A-F) growing
together) were grown in 6 different types of media during 9 days.
The supernatant and biomass extracts of the bacteria growing alone and 6 bacteria
growing together (grown in L1 containing sucrose) did not show any antimalarial activity. The
IC50 concentration of almost all the bacterial strains (except L. alexandrii) was >47600 ng/mL
and the SI was 1. The IC50 of L. alexandrii supernatant extracts was >28000 ng/mL, and the SI
was <1.7 (Table 11-appendix B).
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SEM images
SEM of 8 week-old R. reptotaenium culture biomass showed several bacteria attached to
the cell walls of the filamentous R. reptotaenium (Fig. 20a). These bacteria exhibit various
morphologies and sizes (Fig. 20b). At least one bacterial strain secretes extracellular
polysaccharide webby projections into R. reptotaenium cells (Fig. 20c&d). These webby
projections may explain in part why all former attempts to isolate axenic R. reptotaenium
cultures have been unsuccessful. Strong antibiotic treatments and physical attempts (micropipette
isolation) to separate the cell-wall-associated bacteria may significantly damage the
cyanobacterial cells (Casamatta et al. 2012).
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a

b

c

d

Figure 20. SEM images of biomass samples of 8 week-old R. reptotaenium culture. (a) R.
reptotaenium filaments with several associated bacteria on their cell walls (4,000X); (b)
bacterium (red arrow) attached on R. reptotaenium filament (20,000X); (c, d) bacteria attached to
R. reptotaenium filaments via extracellular polysaccharide webby projections (red arrows)
(40,000X and 50,000X).
Metagenomics (16S) amplicon sequencing results showed that in addition to
Cyanobacteria, there are dominant bacteria in the culture from the phyla of Bacteroidetes,
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Planctomycetes, and Proteobacteria, with 50% of the community composition being from the (αProteobacteria subphylum (Fig. 21).

Figure 21. The relative abundance of four most dominant bacterial phyla in R. reptotaenium 8
weeks-old culture.
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DISCUSSION
The antimalarial activity of R. reptotaenium extracts
Overall, the R. reptotaenium supernatant extracts showed more potent antimalarial
activity than the biomass extracts. For example, the antimalarial activity of the 8 week-old
supernatant crude extracts was 28 times more potent than the biomass crude extracts of the same
age (IC50 196 ng/ml to IC50 5500 ng/mL) (Fig. 8). In addition, the supernatant-100% acetone
fraction eluted by methanol was 27 times more active than the biomass-100% acetone fraction
eluted by the same solvent (IC50 0.22ng/mL to a ratio of IC50 6 ng/mL) (Fig. 9). The
supernatant-100% acetone fraction eluted by acetonitrile was 38 times more active than the
biomass-100% acetone fraction eluted by the same solvent (IC50 0.5ng/mL to a ratio of IC50 19
ng/mL) (Fig. 10). It is not readily apparent why the antimalarial activity of the supernatants
always outperformed the biomass in the antimalarial assays. We speculate that the underlying
reason is possibly due to dolastatin 10 and MMAD being extracellular compounds, not
intracellular compounds, meaning that R. reptotaenium polycultures can readily excrete these
compounds into their environment. This may also explain why former attempts to isolate
dolastatin 10 from the biomass of sea hare Dolabella auricularia (Pettit et al. 1987, 1993) and
the biomass of the marine cyanobacteria Symploca sp. VP642 (Luesch et al. 2001) produced
substantially smaller yields, at 10-7 % and ~10-2 % dry weight yields, respectively (Pettit et al.
1987, 1993, Luesch et al. 2001). These extremely small yields contributed to the 15 year process
of completely elucidating the chemical structure of dolastatin 10. Dolastatin 10 and MMAD are
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two well-known microtubule inhibitors, that can act against various cancer cells with
picomolar concentration.
The 100% acetone fraction eluted by MeOH and the 100% acetone fraction eluted by
acetonitrile (CH3CN) were more active than antimalarial drugs currently on the market. The
100% acetone fraction eluted by methanol was the most active fraction, inhibiting 50% growth
of P. falciparum parasites at a concentration of 0.22 ng/mL, in contrast to 5.37 ng/mL of
Artemisinin or 7.92 ng/mL of Chloroquine (Fig.22- left). The 100% acetone fraction eluted by
acetonitrile had the highest SI value at 1134 (Fig. 22- right).
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Figure 22. Growth inhibition (IC50) P. faciparum W2 (left) and Selective specificity of
inhibition vs. control (right) of R. reptotaenium extracts compared to the current antimalarial
medicines on the market.
The role of culture duration and the R. reptotaenium associated bacterial community
in producing dolastatin 10
In the process of isolating and culturing the bacteria associated with R. reptotaenium
cultures, the colonies with distinctive colors and morphologies were sequenced by 16S rRNA
gene amplification and identified as six different bacterial strains (Table 6). Five of the six
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bacteria identified through this method belonged to the α-Proteobacteria subphylum, with the
sixth bacterial strain belonging to the Flavobacteria subphylum (Table 6). This single colony
sequencing data was generally similar to the whole genome metagenomic sequencing data, in
which the α-Proteobacteria subphylum accounted for 53%, while the Flavobacteria subphylum
accounted 2% relative abundance over the whole community (Fig. 20). However, no bacterial
strains in Bacteroidetes and Planctomycetes were found by using the single colony sequencing
method, although these phyla accounted for a large percentage of relative abundance, 13.2% and
12.7%, respectively, in the whole genome metagenomic sequencing data (Fig. 20).
Unfortunately, the SEM images could not be used alone to identify the bacterial strains, although
parallel in-situ FISH probes targeting species-specific gene sequences might be able to be used
with TEM for accurate bacterial strain identification. The secondary metabolites of the
heterotrophic bacteria isolated from R. reptotaenium cultures did not show antimalarial activity.
More bacterial isolation should be done to verify whether the bacterial strains in these subphyla
were unculturable or not yet identified, and whether they show any bioactivity. The roles that the
bacterial strains played in producing the suit of dolastatin-like complex of compounds were
inconclusive. However, we have shown strong evidence that dolastatin 10 and its synthetic
analogue MMAD are produced through a novel source, the marine cyanobacteria R.
reptotaenium. At this point, we speculate that the bacteria could be adding a methylene group
(CH2) into MMAD to produce dolastatin 10, or be removing a CH2 group from dolastatin 10 to
generate MMAD (Fig. 23).
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Figure 23. Monomethyl auristatin D (MMAD) was modified from dolastatin 10
Other analogues of dolastatin 10 (Lyngbyastatin 1 and 4, dolastatin 12 and 13) were
isolated from the marine cyanobacteria Lyngbya sp. (Harrigan et al. 1998; Matthew et al. 2007).
Not surprisingly, R. reptotaenium belongs to the same Oscillatoriales order as Symploca sp., and
Lyngbya sp. The Lyngbya sp. and Symploca sp. samples used to extract dolastatin 10 and its
analogues were collected from the field, therefore, it is likely that these cyanobacteria were also
impure, with some marine bacteria living in association with the cyanobacteria. R. reptotaenium
comprised the polyculture in the current study, while also containing some heterotrophic bacteria
living in association with the cyanobacteria. Presently, it is still unknown if dolastatin 10 is
synthesized by only the cyanobacteria or by the interaction between the cyanobacteria and its
associated bacteria. It is evident however that dolastatin 10 and MMAD increased in
concentration as the R. reptotaenium cultures aged. We are unsure of whether the compounds
simply accumulate over time, or whether the bacterial community shifted, causing more
compounds to be synthesized. Evidently more research is needed to better understand the
chemical ecology and genetic basis by which dolastatin 10 and MMAD compounds are produced
in the context of this microbial community.
R. reptotaenium and Black Band Disease
According to Richardson’s hypothesis (2014), BBD was caused by the synergistic
impacts of microcystin-LR toxin produced by R. reptotaenium and sulfide produced by sulfate
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reducing bacteria (Richardson et al. 2014). R. reptotaenium could produce microcystin-LR with
a concentration of 0.02 - 0.04 mg g-1 determined by using the enzyme-linked immunosorbent
assay (ELISA) test (Stanić et al. 2011). However, in the process of isolating dolastatin 10 and
MMAD from R. reptotaenium polycultures, we did not see any compound with a molecular
weight of 995 - microcystin LR. The Richardson group did use the high-performance liquid
chromatography (HPLC) to isolate the microcystin-LR peak and compared it to the standard.
However, the microcystin-LR yield was reported based on the results of an ELISA test. We still
do not know whether the R. reptotaenium polycultures shift compositionally over time, and cease
production of MC-LR, or as in the case of Richardson (2014) whether the antibodies in the
ELISA test kit simply showed cross-reactivity with compounds other than microcystin-LR. It is
still inconclusive as to whether microcystin-LR is the main cause of BBD or whether the
cytotoxicity of the suit of dolastatin-like complex of compounds induces coral fatality. Lastly,
the potential for the dolastatin-like complex to induce Black Band Disease in corals should be
also carefully studied, given the destructiveness of this disease on corals worldwide.
What is dolastatin 10 and MMAD?
Dolastatin 10 and MMAD are two well-known microtubule inhibitors with important
medical applications. Dolastatin 10 can act against various cancer cells by inhibiting microtubule
assembly, then inducing cell cycle arrest and apoptosis. Dolastatin 10 has also shown potent
antimalarial activity by inhibiting 50% of P.falciparum with only 10-10 M (Fennell et al. 2003).
Despite the promising preclinical data, the phase II trial of dolastatin 10 was not successful and
further clinical trials of dolastatin 10 are not recommended, due to its significant toxicity at the
maximum tolerated dose (von Mehren et al. 2004; Perez et al. 2005). MMAD had a clinical
application as a playload in antibody-drug conjugates (ADCs) (Senter and Sievers 2012) despite
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slightly less potency than dolastatin 10 (Miyazaki et al. 1995). ADCs, an important class of
potent biopharmaceutical drugs, are designed to kill only cancer cells and leave healthy cells
undamaged (Bakhtiar 2016). ADCs contain 3 parts: a monoclonal antibody, a linker, and a
playload (a cytotoxic anticancer compound) (Zolot, Basu, and Million 2013). MMAD can be
attached to a linker and subsequently conjugated to monoclonal antibodies because it has a
secondary amine at the N-terminus, a chemical characteristic dolastatins 10 do not have
(Maderna et al. 2014; Senter and Sievers 2012). After being released into the cancer cells,
MMAD will inhibit microtubule assembly, subsequently inducing cell apoptosis.
Dolastatin 10 and MMAD are still very expensive on the current pharmaceutical market.
Respectively, dolastatin 10 and MMAD cost approximately $900 and $500 per mg. Further
research can potentially focus on producing R. reptotaenium cultures able to synthesize
dolastatin 10 and MMAD in a shorter amount of time. Such research may lead to increased
yields of dolastatin 10 and MMAD. Finally, more experiments should be conducted to determine
the genetic or biological pathways of dolastatin 10 and the dolastatin-like complex of
compounds. Once such principles are uncovered, dolastatin may be produced on an industrial
scale at a far cheaper market price by cloning the gene into E-coli.
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L1 Medium
Guillard and Hargraves (1993)
This enriched seawater medium is based upon f/2 medium (Guillard and Ryther 1962)
but has additional trace metals. It is a general-purpose marine medium for growing coastal algae.
To prepare, begin with 950 mL of filtered natural seawater. Add the quantity of each
component as indicated below, and then bring the final volume to 1 liter using filtered natural
seawater. The trace element solution and vitamin solutions are given below. Autoclave. Final pH
should be 8.0 to 8.2
Component

Stock Solution

Quantity

Molar Concentration in
Final Medium

NaNO3

75.00 g L-1 dH2O

1 mL

8.82 x 10-4 M

NaH2PO4 ⋅ H2O

5.00 g L-1 dH2O

1 mL

3.62 x 10-5 M

Na2SiO3 ⋅ 9H2O

30.00 g L-1 dH2O

1 mL

1.06 x 10-4 M

Trace element solution

(see recipe below)

1 mL

---

Vitamin solution

(see recipe below)

0.5 mL

---
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L1 Trace Element Solution
To 950 mL dH2O add the following components and bring final volume to 1 liter with dH2O.
Autoclave.
Component

Stock Solution

Quantity

Molar Concentration
in Final Medium

Na2EDTA ⋅ 2H2O

---

4.36 g

1.17 x 10-5 M

FeCl3 ⋅ 6H2O

---

3.15 g

1.17 x 105 M

MnCl2 ⋅ 4H2O

178.10 g L-1 dH2O

1 mL

9.09 x 10-7 M

ZnSO4 ⋅ 7H2O

23.00 g L-1 dH2O

1 mL

8.00 x 108 M

CoCl2 ⋅ 6H2O

11.90 g L-1 dH2O

1 mL

5.00 x 10-8 M

CuSO4 ⋅ 6H2O

2.50 g L-1 dH2O

1 mL

1.00 x 108 M

Na2MoO4 ⋅ 2H2O

19.90 g L-1 dH2O

1 mL

8.22 x 10-8 M

H2SeO3

1.29 g L-1 dH2O

1 mL

1.00 x 10-8 M

NiSO4 ⋅ 6H2O

2.63 g L-1 dH2O

1 mL

1.00 x 10-8 M

Na3VO4

1.84 g L-1 dH2O

1 mL

1.00 x 10-8 M

K2CrO4

1.94 g L-1 dH2O

1 mL

1.00 x 10-8 M
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f/2 Vitamin Solution
(Guillard and Ryther 1962, Guillard 1975)
First, prepare primary stock solutions. To prepare final vitamin solution, begin with 950 mL of
dH2O, dissolve the thiamine, add the amounts of the primary stocks as indicated in the quantity
column below, and bring final volume to 1 liter with dH2O. At the NCMA we autoclave to
sterilize. Store in refrigerator or freezer

Component

Primary Stock

Quantity

Solution

Molar Concentration in
Final Medium

---

200 mg

2.96 x 10-7 M

Biotin (vit. H)

0.1 g L-1 dH2O

10 mL

2.05 x 10-9 M

Cyanocobalamin (vit. B12)

1.0 g L-1 dH2O

1 mL

3.69 x 10-10 M

Thiamine ⋅HCl (vit. B1)
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Table 7. Antimalarial activities of R. reptotaenium supernatant and biomass crude extracts as a
function of culture duration. The antimalarial potential of bioactive metabolites was evaluated in
vitro on a CQ-sensitive strain (P. falciparum D6) and a CQ-resistant strain (P. falciparum W2).
Vero cells (monkey kidney cells) were used to estimate the toxicity of bioactive metabolites. W2
strain generally shows the same response; exceptions are indicated by parentheses ().
Type of

P. falciparum D6

VERO

P. falciparum D6

(W2) IC50 (ng/mL)

IC50

(W2) SI

Length of culturing
extracts
2 weeks

19700 (15060)

>47600

>2 (>3)

3 weeks

1100 (600)

4210

4 (7)

4 weeks

1160 (970)

>4760

>4 (>5)

5 weeks

4030 (3090)

>47600

>12 (>15)

6 weeks

<196

26780

137

8 weeks

<196

>47600

>243

2 weeks

27900 (17100)

>47600

>1.7 (>2.8)

3 weeks

5300

>47600

>9

4 weeks

5300

>47600

>9

5 weeks

7700 (6500)

>47600

>6 (>7)

6 weeks

2500 (4800)

>47600

>19 (>9.9)

8 weeks

3150 (5500)

>47600

>15 (>8.7)

Supernatant
crude
extracts

Biomass
crude
extracts
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Table 8. Antimalarial activities of R. reptotaenium supernatant and biomass extracts purified by
different concentrations of methanol (MeOH) followed by acetone.
P. falciparum D6 (W2)
Types of

Purified

VERO IC50

P. falciparum

(ng/mL)

D6 (W2) SI

IC50
extracts

fraction
(ng/mL)
Water

NA

4760

NA

20% MeOH

NA

4760

NA

40% MeOH

NA

4760

NA

Supernatant

60% MeOH

3630 (2290)

4760

>1.3 (>2.1)

extract

80% MeOH

710 (523)

4760

>7 (>9)

100% MeOH

1.6 (1)

47.6

>30 (>48)

0.33 (0.22)

47.6

>144 (>216)

Water

114 (325)

4760

>42 (15)

20% MeOH

114 (325)

4760

>42 (15)

40% MeOH

4420 (3140)

4760

>1.1 (>1.5)

Biomass

60% MeOH

328 (220)

4760

>15 (>22)

extract

80% MeOH

17 (13)

476

>28 (>37)

100% MeOH

2 (2)

47.6

>24 (>24)

15 (6)

476

>32 (>79)

100%
Acetone

100%
Acetone
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Table 9. Antimalarial activities of R. reptotaenium supernatant and biomass extracts purified by
different concentrations of acetonitrile followed by acetone
P. falciparum D6 (W2)
Types of

VERO IC50
Purified fractions

IC50

P. falciparum

extracts

(ng/mL)
(ng/mL)

D6 (W2) SI

Water

>23800

>23800

1

20% Acetonitrile

>36890

>36890

1

40% Acetonitrile

>3570

>3570

1

60% Acetonitrile

3000 (2160)

>3570

>1.2 (>1.7)

80% Acetonitrile

480 (412)

>1190

>2.5 (>2.9)

100% Acetonitrile

2960 (2380)

>3570

>1.2 (>1.5)

100% Acetone

0.6 (0.5)

567

945 (1134)

Water

543 (690)

>23800

>43.8 (>34.5)

20% Acetonitrile

11400 (1670)

>29750

>2.6 (>17.9

40% Acetonitrile

>2380

>2380

1

60% Acetonitrile

2960 (1862)

>3570

>1.2 (1.9)

80% Acetonitrile

586 (136)

>1190

>2 (>8.7)

100% Acetonitrile

1097 (180)

>1190

>1.1 (>6.6)

10 (19)

>357

>35.7 (>18.6)

Supernatant
extract

Biomass
extracts

100% Acetone
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Table 10. Bacteria strains isolated from R. reptotaenium cultures.
Labrenzia alexandrii

Alphaproteobacteria; Gram (-); Size: 0.5-0.7 x 0.9-3.0µm; rod
shape; slightly pink colony; aerobic anoxygenic phototrophs ;
salinity: 1-10% NaCl; Biotin and thiamine are required as growth
factors; Isolated from cultured cells of the marine dinoflagellate
Alexandrrium lusitanicum

Labrenzia aggregata

Alphaproteobacteria; Gram (-); 1.9 um x 0.8 um; rod shape; white to
cream colony; obligate aerobic; salinity: 0.3-6%; not require vitamin
to grow

Stappia indica

Alphaproteobacteria; Gram (-); 1.0 um x 1.0 um; rod shape; white
colony; obligate aerobic; salinity 0.5-11% NaCl; not require vitamin
to grow

Koidiimonas

Alphaproteobacteria; Gram (-); 1.3–1.4 mm x 0.25 mm; rod shape;

gwangyangensis

translucent, creamy white colony; obligate aerobic; optimal NaCl
2%; isolated from Korea

Muricauda aquimarina

Flavobacteria; Gram (-); 0.2–0.5 mm x 2.5–6.0 mm; rod shape;
golden yellow colony; aerobic; 1-10% NaCl; isolated from Korea

Phyllobacterium sp.

Alphaproteobacteria; Gram (-); rod shape; transparent colony;
aerobic; 1% NaCl
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Table 11. Antimalarial activities of metabolites in the extracts of different bacterial strains living
in association of R. reptotaenium culture.
Types of

P. falciparum D6
Baterial strains

extracts

P. falciparum
VERO IC50

(W2) IC50 (ng/mL)

D6 (W2) SI

Labrenzia alexandrii

28000 (37000)

>47600

1.7 (1.2)

Labrenzia aggregata

>47600

>47600

1

Kordiimonas sp.

>47600

>47600

1

44000 (46000)

>47600

>1

Stappia sp.

>47600

>47600

1

Phyllobacterium sp.

>47600

>47600

1

6 bacteria growing together

>47600

>47600

1

Labrenzia alexandrii

>47600

>47600

1

Labrenzia aggregata

>47600

>47600

1

Kordiimonas sp.

>47600

>47600

1

Muricauda sp.

>47600

>47600

1

Stappia sp.

>47600

>47600

1

Phyllobacterium sp.

>47600

>47600

1

6 bacteria growing together

>47600

>47600

1

Supernatant
Muricauda sp.
extract

Biomass
extracts
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Table 12. Antimalarial activities of different parts of the active fractions (supernatant-acetone
100%)
P. falciparum D6 (W2)
VERO IC50 P. falciparum D6 (W2) SI
Parts

IC50
(ng/mL)
(ng/mL)

0-2.5 min

>1190

>1190

1

2.5-4.5 min

<4.9

587.8

120

4.5-9.0 min

156.1 (108.6)

>1190

>7.6 (>11)

9.0-12.0 min

>1190

>1190

1

Combination

25 (13.8)

>1190

>47.6 (>86.5)
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Table 13. The relative abundance (%) of major bacterial phyla and subphyla in R. reptotaenium
2 weeks-old and 8 weeks-old culture.
% composition of the whole community
2 weeks

8 weeks

13.2

17.8

Rhodothermi

7.8

9.1

Saprospirae

0.9

3.7

Cytophagia

4.0

3.4

Flavobacteriia

0.6

1.6

7.6

4.1

7.6

4.1

12.7

15.2

Phycisphaerae

3.5

2.1

Planctomycetia

9.2

13.1

60.4

55.0

Alphaproteobacteria

58.6

52.9

Betaproteobacteria

0.1

0.1

Gammaproteobacteria

1.6

2.1

Other

6.1

7.9

Total

100

100

Bacteroidetes

Cyanobacteria
Oscillatoriophycideae
Planctomycetes

Proteobacteria
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